Scholars Central

Research articlePublished 25 Aug 2023

Efficacy of Ceftolozane/Tazobactam in Infections with Multidrug-Resistant Gram-Negative Bacteria: A Preliminary Clinical Experience in a Highly Endemic Hospital

Authors: Lucia Brescini, Sara Mazzanti, Luca Battistelli, Gianluca Morroni, Francesco Pallotta, Bianca Candelaresi, Silvia Olivieri, Francesco Ginevri, Giulia Cesaretti, Raffaella Donati, Matteo Cimatti, Rosaria G Polo, Vanessa Di Muzio, Michele Di Prinzio, Oriana Cornacchini, Marcello Tavio, Andrea Giacometti, Abele Donati, Elisabetta Cerutti, Francesco Barchiesi

1Infectious Diseases Clinic, Azienda Ospedaliero University Delle Marche, Ancona, Italy; 2Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Ancona, Italy; 3Hospital Pharmacy, Azienda Ospedaliero University Delle Marche, Ancona, Italy; 4Anesthesia, Transplant and Surgical Intensive Care Unit, Azienda Ospedaliero University delle Marche, Ancona, Italy; 5Clinic of Anesthesia and General Resuscitation, Respiratory and Major Trauma, Azienda Ospedaliero University delle Marche Ancona, Italy

Journal of Infectious Diseases & Therapy

Volume 11 · Issue 5 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Ceftolozane/Tazobactam is a new cephalosporin/beta-lactams inhibitor combination proven to be a drug with efficacy against urinary tract infections, abdominal infections and nosocomial ventilator-associated pneumonia, supported by multi-resistant Gram-negative bacteria. Methods: This retrospective study considerated a cohort of 85 patients (≥ 18 years ), with a Gram-negative infection diagnosed between October 2017 and December 2020, treated with at least 72 hours of C/T therapy. The aim was to evaluate the efficacy, tolerability and to analyze any factors associated with a negative outcome. Results: The clinical success achieved in patients treated with ceftolozane/tazobactam in this coorte was 59%. Risk factors independently associated with mortality were neutropenia (p=0.02) and ICU stay (p=0.009). High mortality in ICU is related to complexity of patients with multiple devices and concomitant infections that needed combination of antibiotic therapy. Conclusion: Ceftolozano/tazobactam represents a therapy of choice in infections by Gram-MDR bacteria, also in that which multiple comorbidity and long hospital stay.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases & Therapy
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Lucia Brescini”
  • BylineArticles whose byline prints “Sara Mazzanti”
  • BylineArticles whose byline prints “Luca Battistelli”
  • BylineArticles whose byline prints “Gianluca Morroni”
  • BylineArticles whose byline prints “Francesco Pallotta”
  • BylineArticles whose byline prints “Bianca Candelaresi”
  • BylineArticles whose byline prints “Silvia Olivieri”
  • BylineArticles whose byline prints “Francesco Ginevri”